References

Address for correspondence: Elizabeth R. Gleim, Department of Biology and Environmental Studies, Hollins University, 8003 Fishburn Dr, PO Box 9615, Roanoke, VA 24020, USA; email: egleim@hollins.edu

Hepatic Brucellosa Diagnosis and Long-Term Treatment, France

Marie Amsilli, Olivier Epaulard, Jean-Paul Brion, Patricia Pavese, Christian Letoublon, Isabelle Pelloux, Max Maurin

Author affiliations: Centre Hospitalier Universitaire de Grenoble, Grenoble, France (M. Amsilli, O. Epaulard, J.-P. Brion, P. Pavese, C. Letoublon, I. Pelloux, M. Maurin); Université Grenoble Alpes, Grenoble (O. Epaulard, C. Letoublon, M. Maurin)

DOI: https://doi.org/10.3201/eid2505.180613

We report a case of hepatic brucellosa in France. This diagnosis may be suspected in any patient who has a liver abscess after traveling to a brucellosa-endemic area. Brucella spp. may be detected by PCR in the liver tissue or suppuration. Abscess drainage and prolonged antimicrobial therapy help achieve healing.

Brucellosa is a zoonosis found worldwide (1,2) caused by gram-negative, facultative intracellular bacteria of the genus Brucella. Approximately 500,000 new infections are diagnosed annually, mainly in the Mediterranean basin, the Middle East, Latin America, and Asia (1–3). Brucellosa is a rare and mainly imported disease in other countries, including France (1,4). Brucella infection usually occurs after contact with infected animals or consumption of contaminated unpasteurized dairy products. Hepatic brucellosa (HB) is a chronic form of brucellosa arising up to 40 years after initial infection (1,3,5). Only 60 cases (1%–2% of all brucellosa infections) have been reported in English-language literature since 1904 (1,3,5,6). HB is associated with nonspecific systemic clinical symptoms (e.g., fever, malaise, weight loss, upper abdominal pain), moderate biologic abnormalities, and typical hypodense hepatic lesion with peripheral enhancement and central calcification (1–3,5,6).

In April 2015, a previously healthy 55-year-old woman was referred to Grenoble University Hospital after 7 days of fever, asthenia, and weight loss. She had lived in France for 20 years, but had been born in and had traveled every year to Algeria. Her clinical examination was unrevealing. Blood tests showed moderate inflammation and anicteric cholestasis (Table). Hepatic ultrasound (HUS) and computed tomography (CT) confirmed a defect 60 mm in diameter in liver segments IV and VIII with several subcapsular liquid collections and central calcification (Appendix Figure, panel A, https://wwwnc.cdc.gov/EID/article/25/5/18-0613-app1.pdf).

Blood cultures remained sterile. Serologic test results were negative for HIV, amebiasis, and echinococcosis, but positive for Yersinia enterocolitica serotype O:9 and Brucella sp. (Table). HUS-guided drainage of the abscess yielded thick purulent fluid. Fluid cultures were negative, but we detected Brucella melitensis DNA by PCR amplification and sequencing of the 16S rRNA–encoding gene. Histological findings of liver tissue were compatible with a chronic abscess. We confirmed diagnosis on 2 occasions by PCR detection of Brucella DNA in the liver abscess, as previously reported (1,3,5–7). The serologic profile was suggestive of chronic brucellosis combining low IgM but strong IgG Brucella antibody titers (1,3,5,7). However, Brucella serologic diagnosis is poorly specific, due to antigenic cross-reactions (e.g.,...
Y. enterocolitica 0:9) and residual antibodies related to past exposure in patients from *Brucella*-endemic areas (3). *Brucella* cultures of blood or tissue samples and PCR on serum are usually not contributing factors in chronic focal brucellosis (1,3,5–7).

Upon diagnosis of hepatic brucellosis, we administered doxycycline plus rifampin, replacing initial empirical treatment with ceftriaxone and metronidazole for suspected pyogenic abscess. After 2 months of treatment, clinical and biologic abnormalities had regressed. CT with contrast revealed substantial reduction of the abscess, but also thrombosis of the median hepatic vein, infiltration of the gallbladder, and new lesions in segment VIII (Appendix Figure, panel B). We continued the antimicrobial therapy and surgery was recused. After 6 months of treatment, antibody titers were decreasing (Table). Three months later, positron emission tomography highlighted intense focal uptake in segments IV and VIII. Fluid from a second HUS-guided drainage was positive by *Brucella*-specific PCR test (Table). We changed the treatment to trimethoprim/sulfamethoxazole plus doxycycline for another 6 months. At completion, magnetic resonance imaging showed abscess reduction with stable central calcification.

HB patients are difficult to manage because of lack of optimized treatment (1,8), and clinical course is the only reliable evidence in disease control (1,3,9). Our treatment was conservative, including 15 months of antimicrobial therapy and repeated HUS drainages. We continued treatment despite worsening radiological findings (including onset of cholecystitis and deep vein thrombosis) on the basis of early favorable clinical course and patient compliance (1–3,5,8,9). We monitored the improvement of radiological lesions using positron emission tomography–computed tomography and magnetic resonance imaging, both of which are sensitive for diagnosis although not assessed for monitoring, for 15 months after treatment. Few studies have described the radiological evolution over time in complicated cases (1–3,5,8), but persistence of calcifications is usual in HB (2,3,9).

Administration of doxycycline plus rifampin, an aminoglycoside, or both is currently recommended for brucellosis (1–3); choice and duration of treatment must be individualized to the patient’s symptomatology and treatment tolerability (1–3,8,9) and the involved tissues (2,8). Surgical resection and percutaneous drainage of the abscess are both reported as effective adjunctive therapy, with surgery indicated when evacuation of pus is ineffective or clinical symptoms persist despite drainage (1–3,5,6). A short course of an aminoglycoside could have been added at the time of radiological diagnosis of complications, as reported in other focal brucellosis with poor clinical evolution (2,8,9), in which a prolonged regimen (6–52 weeks) is also described (3,8,9). As of January 2019, after 2.5 years of treatment and follow-up care, our patient is considered cured. Relapses mainly occur within a few months of treatment completion but may occasionally occur later (2,5).

Any patient with characteristic liver abscess after traveling in brucellosis-endemic areas should undergo serologic testing for a presumptive diagnosis, and PCR testing of abscess fluid or hepatic tissue for confirmation of brucellosis. A conservative treatment combining long-term antimicrobial therapy and repeated HUS drainage may be effective. Long-term clinical comprehensive follow-up is required.

---

**Table.** Diagnostic and blood tests on patient with hepatic brucellosis, Grenoble, France

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference value</th>
<th>2015 Apr</th>
<th>2015 Nov</th>
<th>2016 Jan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rose Bengal plate agglutination test (bioMérieux, <a href="https://www.biomerieux.com">https://www.biomerieux.com</a>)</td>
<td>NA</td>
<td>Strongly positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Tube agglutination test (Elitech, <a href="https://www.elitechgroup.com">https://www.elitechgroup.com</a>)</td>
<td>&gt;80</td>
<td>160</td>
<td>20</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Immunofluorescence IgM (BioRad, <a href="http://www.bio-rad.com">http://www.bio-rad.com</a>)</td>
<td>&gt;40</td>
<td>&lt;20</td>
<td>&lt;20</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Immunofluorescence IgG (BioRad)</td>
<td>&gt;80</td>
<td>160</td>
<td>160</td>
<td>320</td>
</tr>
<tr>
<td><em>Brucella</em> PCR testing of liver tissue biopsies</td>
<td>NA</td>
<td>Positive for 16S rDNA</td>
<td>NA</td>
<td>Positive for bcsps1 gene</td>
</tr>
<tr>
<td>Blood cultures</td>
<td>NA</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Liver abscess and tissue cultures† (bacteria, fungi and mycobacteria)</td>
<td>NA</td>
<td>Negative</td>
<td>Negative</td>
<td>NA</td>
</tr>
<tr>
<td>C-reactive protein, mg/L</td>
<td>&lt;3</td>
<td>56</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Fibrinogen, g/L</td>
<td>2.1–4.1</td>
<td>6.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count, G/L</td>
<td>4–11</td>
<td>8.5</td>
<td>5</td>
<td>4.9</td>
</tr>
<tr>
<td>Neutrophil count, G/L</td>
<td>1.6–8.8</td>
<td>5.9</td>
<td>2.5</td>
<td>2.1</td>
</tr>
<tr>
<td>Thrombocyte count, G/L</td>
<td>150–400</td>
<td>489</td>
<td>287</td>
<td>284</td>
</tr>
<tr>
<td>Bilirubin, μmol/L</td>
<td>3–17</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Alkaline phosphatase, IU/L</td>
<td>50–136</td>
<td>158</td>
<td>85</td>
<td>69</td>
</tr>
<tr>
<td>γ-glutamyl transferase, IU/L</td>
<td>5–55</td>
<td>107</td>
<td>31</td>
<td>23</td>
</tr>
<tr>
<td>Aspartate aminotransferase, IU/L</td>
<td>15–37</td>
<td>20</td>
<td>16</td>
<td>14</td>
</tr>
<tr>
<td>Alanine aminotransferase, IU/L</td>
<td>12–78</td>
<td>28</td>
<td>26</td>
<td>22</td>
</tr>
</tbody>
</table>

*NA, not applicable.
†Tissues were cultured for bacteria, fungi, and mycobacteria.
Human Monkeypox in Sierra Leone after 44-Year Absence of Reported Cases

Mary G. Reynolds, Nadia Wauquier, Yu Li, Panayampalli Subbian Satheshkumar, Lansana D. Kanneh, Benjamin Monroe, Jacob Maikere, Gbessay Saffa, Jean-Paul Gonzalez, Joseph Fair, Darin S. Carroll, Amara Jambai, Foday Dafae, Sheik Humarr Khan, Lina M. Moses

Address for correspondence: Marie Amsili, Centre Hospitalier Universitaire Grenoble Alpes—Service de Maladies Infectieuses, BP 217, Grenoble 38043, France; email: marieamsili@gmail.com

We thank Linda Northrup for English editing. We thank the patient for consenting to publication of her clinical data.

About the Author
Dr. Amsili is an infectious and tropical diseases physician. Her research interests are emerging infectious diseases and medicine quality.

Acknowledgments

References


We note the reemergence of human monkeypox in Sierra Leone following a 44-year absence of reported disease. The persons affected were an 11-month-old boy and, several years later, a 35-year-old man. The reappearance of monkeypox in this country suggests a need for renewed vigilance and awareness of the disease and its manifestations.

Monkeypox, a tropical zoonosis with an estimated death rate of 15% in children, is a resurgent presence in several countries in West and Central Africa (1,2). Before 2000, only 21 cases of monkeypox had been reported from these regions, including a single case in Sierra Leone in 1970 (3). The disease had not been observed in Sierra Leone since then, although a 2007 survey for orthopoxvirus antibodies among populations near Kenema, Sierra Leone, generated evidence to suggest ongoing circulation of orthopoxviruses in the area (4).

On March 18, 2014, a resident of Kpetema town in Sierra Leone brought her 11-month-old son to the community health post in nearby Mano village. There, he was evaluated for fever and released. The child failed to improve, and the next day his mother again sought medical care, this time from the community health center (CHC) in Koribondo. At this time, the child remained febrile and was exhibiting a